Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Patent
1993-06-14
1999-11-09
Feisee, Lila
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
4241811, 4241781, 4241381, 4241341, 4241411, 4241351, 4241361, 4241551, 5303917, 5303873, 5303875, 5303877, A61K 38395, C07K 1630, C07K 1900, C12N 512
Patent
active
059808969
ABSTRACT:
The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4507391 (1985-03-01), Pukel et al.
patent: 4579827 (1986-04-01), Sakamoto et al.
patent: 4612282 (1986-09-01), Schlom et al.
patent: 4676980 (1987-06-01), Segal
patent: 4708930 (1987-11-01), Kortright et al.
patent: 4713351 (1987-12-01), Knauf
patent: 4713352 (1987-12-01), Bander et al.
patent: 4737579 (1988-04-01), Helstrom et al.
patent: 4753894 (1988-06-01), Frankel et al.
Schreiber, et al., "An Unmodified Anticarcinoma Antibody, BR96, Localizes to and Inhibits the Outgrowth of Human Tumors in Nude Mice", Cancer Reserch, 52:3262-3266 (1992) (Exhibit 131).
Siegell, et al., "In Vitro and In Vivo Characteriation of BR96 sFv-PE40", Journal of Immunology, 152:2377-2384 (1994) (Exhibit 132).
Friedman, et al., "BR96 sFv-PE40, a Potent Single-Chain Immunotoxin That Selectively Kills Carcinoma Cells", Cancer Research, 53:334-339 (1993) (Exhibit 133).
Willner, et al., 6-Maleimidocaproyl) hydrazone of Doxorubicin-A New Derivative for the Preparation of Immunoconjugates of Doxorubicin, Bioconjugate Chem., 4:521-527 (1993) (Exhibit 134).
Yarnold, et al., "Chimerization of Antitumor Antibodies via Homologous Recombination Conversion Vectors", Cancer Research, 54:506-512 (1994) (Exhibit 135).
Friedman, et al., Antitumor Activity of the Single-Chain Immunotoxin BR96 sFv-PE40 Against Established Breast and Lung Tumor Xenografts:, Journal of Immunology, 150:3054-3061 (1993) (Exhibit 136).
Zhao, et al., "Determination of Immunoreactivity of Doxorubicin Antibody Immunoconjugates by a Ley Competitive RIA", Bioconjugate Chem., 3:549-553 (1992) (Exhibit 137).
Abraham, et al., "The Influence of Periodate Oxidation on Monoclonal Antibody Avidity and Immunoreactivity", Journal of Immunological Methods 144:77-86 (1991) (Exhibit 138).
Chang, et al., "Crystallization and Preliminary X-ray Analysis of the Monoclonal Anti-tumor Antibody BR96 and its Complex with the Lewis Y Determinant", J. Mol. Biol. (1994) 235:372-376 (Exhibit 139).
Friedman et al. J. Immunol. 150:3054-61 1993.
Siegall et al. Bioconjugate Chem. 3:302-7 1992.
Pastan et al; Annu Rev Biochem 61:331-341 1992.
Schreiber et al., Cancer Res 52:3262-6 1992 (Jun. 15).
Stoerz et al., PNAS USA 83:1453-7, 1986.
Hellstrom et al. Cancer Res 50:2183-90, 1990 (Apr. 1).
Harris et al. Tibtech 11:42-44, 1993.
Osband et al,. Immunol. Today 11:193-5, 1990.
Trail et al. Science 261:212-215, Jul. 9, 1993.
Hird et al. in "Genes and Cancer", Carney et al., Ed., John Wiley & Sons Ltd., 1990 pp. 83-9.
Schlom, in "Molecular Foundations of Oncology", Broder, Ed., Williams & Wilklins, 1991, 95-134.
Kimmel et al., J. Neurosurg. 66:161-171, 1987.
Hellstrom et al., "Antitumor Effects of L6, An IgG2a Antibody that Reacts with Most Human Carcinomas", Proc. Natl. Acad. Sci. USA 83:7059-7063 (1986).
Drebin et al., "Monoclonal Antibodies Specific for the Neu Oncogene Product Directly Mediate Anti-Tumor Effects In Vivo", Oncogene 2:387-394 (1998).
Papsidero, "Recent Progress in the Immunological Monitoring of Carcinomas Using Monoclonal Antibodies", Sem. in Surg. Onc. 1:171-181 (1985).
Schlom and Weeks, "Potential Clinical Utility of Monoclonal Antibodies in the Management of Human Carcinomas", Important Adv. Oncol. pp. 170-192 (1985).
Allum et al., "Monoclonal Antibodies in the Diagnosis and Treatment of Malignant Conditions", Surg. Ann. 18:41-64 (1986).
Houghton and Scheinberg, "Monoclonal Antibodies: Potential Applications to the Treatment of Cancer", Sem. in. Oncol. 13(2):165-179 (1986).
Fink and Clarke, "Monoclonal Antibodies as Diagnostic Reagents for the Identification and Characterization of Human Tumor Antigens", Prog. Clin. Pathol. 9:121-133 (1984).
Johnston, "Applications of Monoclonal Antibodies in Clinical Cytology as Exemplified by Studies with Monoclonal Antibody B72.3", Acta. Cytol. 1(5):537-556 (1987).
Young et al., "Production of Monoclonal Antibodies Specific for Two Distinct Steric Portions of the Glycolipid Anglio-N-Tiosylceramide (Asialo GM.sub.2)", J. Exp. Med. 150:1008-1019 (1979).
Kniep et al., "Gangliotriaoslyceramide (Asialo GM.sub.2) A Glycosphingolipid Marker for Cell Lines Derived from Patients with Hodgkin's Disease", J. Immunol. 131:1591-1594 (1983).
Rosen et al., "Analysis of Human Small Cell Lung Cancer Differentiation Antigens Using A Panel of Rat Monoclonal Antibodies", Cancer Res. 44:s052-2061 (1984).
Varki et al., "Antigens Associated with a Human Lung Adenocarcinoma Defined by Monoclonal Antibodies", Cancer Res. 44:681-685 (1984).
Embleton and Garnett, "Antibody Targeting of Anti-Cancer Agents", in "Monoclonal Antibodies for Cancer Detection and Therapy" pp. 317-344, Academic Press (1985).
Domingo and Trowbridge, "Transferrin Receptor as a Target for Antibody-Drug Conjugates", Methods Enzymol. 112:238-247 (1985).
Kohler and Milstein, "Continous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", Nature (London) 256:495-497 (1975).
Oi et al., "Immunoglobulin Gene Expression in Transformed Lymphoid Cells", Proc. Natl. Acad. Sci. USA 80:825 (1983).
Potter et al., "Enhancer-Dependent Expression of Human K Immunoglobulin Genes Introduced Into Mouse Pre-B Lymphocytes by Electroporation", Proc. Natl. Acad. Sci. USA 81:7161-7165 (1984).
Morrison et al., "Chimeric Human ANtibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains", Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984).
Sahagan et al., "A Genetically Engineered Murine/Human Antibody Retains Specificity for Human Tumor-Associated Antigen", J. Immunol. 137:1066-1074 (1986).
Sun et al., "Chimeric Antibody with Human Constant Regions and Mouse Variable Regions Directed Aganist Carcinoma-Associated Antigen 17-1A", Proc. Natl. Acad. Sci. USA 84:214 (1987).
Boulianne et al., "Production of Functional Chimaeric Mouse/Human Antibody", Nature 312:643 (1984).
Sharon et al., "Expression of a V.sub.H C.sub.K Chimaeric Protein in Mouse Myeloma Cells", Nature 309:364-367 (1984).
Tan et al., "A Human-Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells", J. Immunol. 135:3564-3567 (1985).
Folger et al., "Analysis of Homologous Recombination in Cultured Mammalian Cells", Symp. Quant. Biol. 49:123-138 (1984).
Folger et al., "Patterns of Integration of DNA Microinjected into Cultured Mammalian Cells: Evidence for Homologous Recombination Between Injected Plasmic DNA Molecules", Mol. Cell Biol. 2:1372-1387 (1982).
Kucherlapati, "Homolgous Recombination between Plasmids in Mammalian Cells Can Be Enhanced by Treatment of Input DNA", Proc. Natl. Acad. Sci. USA 81:3153-3157 (1984).
Lin et al., "Recombination in Mouse L Cells Between DNA Introduced into Cells and Homologous Chromosomal Sequences", Proc. Natl. Acad. Sci. USA 82:1391-1395 (1985).
de Saint Vincent et al., "Homologous Recombination in Mammalian Cells Mediates Formation of a Functional Gene from Two
Bruce Kim Folger
Hellstrom Ingegerd
Hellstrom Karl Erik
McAndrew Stephen
Schreiber George J.
Bansal Geetha P.
Bristol--Myers Squibb Company
Feisee Lila
LandOfFree
Antibodies reactive with human carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies reactive with human carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies reactive with human carcinomas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1451895